English: Estradiol and testosterone levels with two to six 7.8-mg 100 µg/day estradiol transdermal patches per week in men with prostate cancer.

"Six transdermal estradiol (7.8 mg.) patches were applied weekly for 8 weeks and then the number of patches was reduced to maintain castrate levels of testosterone." "Hormone responses (mean trough levels using 2 (7.8 mg.) estradiol patches a week to maintain castrate (less than 2 nmol./l. testosterone). Two patches a week were sufficient to maintain castrate testosterone but were changed twice weekly to boost trough estradiol levels, and maintain patch adhesion and patient compliance."

This excerpt and source indicates that the patches used in the study provided a dosage of estradiol of 100 µg/day (the original publication did not specify this): "Available information suggests that for preparations delivering 100 µg/day of oestradiol transdermally (including the Progynova [TS forte] patches used in the original pilot study [5]) [...]":

• (August 2008). "Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer". BJU Int. 102 (4): 442–5. DOI:10.1111/j.1464-410X.2008.07583.x. PMID 18422771. PMC: 2564109.

A review that reproduced the graph from the original publication:

• (October 2006). "Therapy Insight: parenteral estrogen treatment for prostate cancer--a new dawn for an old therapy". Nat Clin Pract Oncol 3 (10): 552–63. DOI:10.1038/ncponc0602. PMID 17019433.